NCT00628732View on ClinicalTrials.gov

A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Solid Tumors
Interventions
DRUG

Cyclophosphamide and Topotecan

Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.

Trial Locations (1)

75235

Children's Medical Center Dallas, Dallas

Sponsors

Collaborators (1)

Metabolic Solutions Inc.
All Listed Sponsors
collaborator

Metabolic Solutions Inc.

INDUSTRY

collaborator

Simmons Cancer Center

OTHER

lead

Children's Medical Center Dallas

OTHER

NCT00628732 - A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter